Skip to main content
SpringerLink
Log in

Treat borderline personality disorder with psychotherapy and concomitant psychiatric disorders with adjuvant pharmacotherapy

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

No class of medications has consistently improved symptoms of borderline personality disorder (BPD) in randomized clinical trials, and no pharmacological treatment has been approved specifically for BPD. Psychotherapy is the treatment of first choice in BPD, and the general consensus is that pharmacotherapy should be used mainly for the treatment of comorbid disorders. However, most patients with BPD are medicated even when they do not have comorbidities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jin J. Borderline personality disorder. JAMA. 2023;329(8):692.

    Article  PubMed  Google Scholar 

  2. Chapman J, Jamil RT, Fleisher C. Borderline personality disorder. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430883/.

  3. Pascual JC, Arias L, Soler J. Pharmacological management of borderline personality disorder and common comorbidities. CNS Drugs. 2023;37(6):489–97.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Shah R, Zanarini MC. Comorbidity of borderline personality disorder: current status and future directions. Psychiatr Clin N Am. 2018;41(4):583–93.

    Article  Google Scholar 

  5. Stone MH. Borderline personality disorder: clinical guidelines for treatment. Psychodyn Psychiatry. 2022;50(1):45–63.

    Article  PubMed  Google Scholar 

  6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edn. 2022. American Psychiatric Publishing. https://doi.org/10.1176/appi.books.9780890425787.

  7. Zimmerman M. Borderline personality disorder. 2023. https://www.msdmanuals.com/professional/psychiatric-disorders/personality-disorders/borderline-personality-disorder-bpd. Accessed 21 Oct 2023.

  8. Simonsen S, Bateman A, Bohus M, et al. European guidelines for personality disorders: past, present and future. Borderline Person Disord Emot Dysregul. 2019;6:9.

    Article  Google Scholar 

  9. Choi-Kain LW, Finch EF, Masland SR, et al. What works in the treatment of borderline personality disorder. Curr Behav Neurosci Rep. 2017;4(1):21–30.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Martín-Blanco A, Ancochea A, Soler J. Changes over the last 15 years in the psychopharmacological management of persons with borderline personality disorder. Acta Psychiatr Scand. 2017;136(3):323–31.

    Article  PubMed  Google Scholar 

  11. Bozzatello P, Rocca P, De Rosa ML, et al. Current and emerging medications for borderline personality disorder: is pharmacotherapy alone enough? Expert Opin Pharmacother. 2020;21(1):47–61.

    Article  CAS  PubMed  Google Scholar 

  12. Soler J, Casellas-Pujol E, Fernández-Felipe I. “Skills for pills”: the dialectical-behavioural therapy skills training reduces polypharmacy in borderline personality disorder. Acta Psychiatr Scand. 2022;145(4):332–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Esther S. Kim & Yvette N. Lamb

Authors
  1. Esther S. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yvette N. Lamb
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yvette N. Lamb.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and conflict of interest

E. S. Kim, a contracted employee of Adis International Ltd/Springer Nature, and Y. N. Lamb, a salaried employee of Adis International Ltd/Springer Nature, declare no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.

Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability

Not applicable.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, E.S., Lamb, Y.N. Treat borderline personality disorder with psychotherapy and concomitant psychiatric disorders with adjuvant pharmacotherapy. Drugs Ther Perspect 40, 17–21 (2024). https://doi.org/10.1007/s40267-023-01042-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-023-01042-9

Search

Navigation